共 272 条
[1]
Bramlage P(2010)The effect of optimal medical therapy on 1-year mortality after acute myocardial infarction Heart 96 604-609
[2]
Messer C(2019)Appropriate secondary prevention and clinical outcomes after acute myocardial infarction according to atherothrombotic risk stratification: the FAST-MI 2010 registry Eur J Prev Cardiol 26 411-419
[3]
Bitterlich N(2017)Angiotensin receptor blockers reduce cardiovascular events, including the risk of myocardial infarction Circulation 135 2085-2087
[4]
Pohlmann C(2018)2017 ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: the task force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC) Eur Heart J 39 119-177
[5]
Cuneo A(2016)2015 ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: task force for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC) Eur Heart J 37 267-315
[6]
Stammwitz E(2000)Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients N Engl J Med 342 145-153
[7]
Tebbenjohanns J(1992)Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators N Engl J Med 327 669-677
[8]
Gohlke H(2003)Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both N Engl J Med 349 1893-1906
[9]
Senges J(2012)Angiotensin-converting enzyme inhibitors or angiotensin receptor blockers are beneficial in normotensive atherosclerotic patients: a collaborative meta-analysis of randomized trials Eur Heart J 33 505-514
[10]
Tebbe U(2006)The effect of valsartan, captopril, or both on atherosclerotic events after acute myocardial infarction: an analysis of the Valsartan in Acute Myocardial Infarction Trial (VALIANT) J Am Coll Cardiol 47 726-733